| Q2 2025 Membership | 115,000 | (CFO) |
| Q2 2025 Capitated Revenue | $352 million | (CFO) |
| Q2 2025 Total Revenue | $356 million | (CFO) |
| Q2 2025 Medical Margin (excl. prior period adjustments) | $39 million / $114 PMPM | (CFO) |
| Q2 2025 Adjusted EBITDA (reported) | -$17 million / -$50 PMPM | (CFO) |
| Q2 2025 Adjusted EBITDA (normalized, excl. prior period adjustments) | -$8 million / -$25 PMPM | (CFO) |
| 1H 2025 Adjusted EBITDA (normalized, excl. prior period adjustments) | -$22 million | (CEO) |
| FY 2025 Revised Adjusted EBITDA Guidance | -$39 million to -$69 million | (CEO) (CFO) |
| FY 2026 Identified EBITDA Improvement Opportunity | $120 million to $170 million | (CEO) |
| Q2 2025 Prior Period Adjustments Impact | -$9 million | (CEO) (CFO) |
| Q2 2025 Operating Expense YoY Change | -13% | (CFO) |
| Workforce Reduction Since Jan 2024 | -25% | (CFO) |
| Liquidity at Quarter End | $39 million | (CFO) |